Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
Axsome Therapeutics presented four new data sets for its migraine drug SYMBRAVO at the American Headache Society annual meeting. The presentations included post-hoc efficacy analyses from the Phase 3 MOMENTUM and INTERCEPT trials, as well as a network meta-analysis comparing SYMBRAVO to gepants.
Key figures
- Drug Name
- SYMBRAVO
- Meeting
- AHS 68th Annual Scientific Meeting
- Presentation count
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.